MA39032A1 - Acide 4- [5- (3-chloro-phénoxy) -oxazolo [5,4-d] pyrimidin -2-yl] -2,6-diméthyl-phénoxy}-acétique destiné à être utilisé dans la prévention ou le traitement d'une insuffisance rénale aiguë - Google Patents
Acide 4- [5- (3-chloro-phénoxy) -oxazolo [5,4-d] pyrimidin -2-yl] -2,6-diméthyl-phénoxy}-acétique destiné à être utilisé dans la prévention ou le traitement d'une insuffisance rénale aiguëInfo
- Publication number
- MA39032A1 MA39032A1 MA39032A MA39032A MA39032A1 MA 39032 A1 MA39032 A1 MA 39032A1 MA 39032 A MA39032 A MA 39032A MA 39032 A MA39032 A MA 39032A MA 39032 A1 MA39032 A1 MA 39032A1
- Authority
- MA
- Morocco
- Prior art keywords
- phenoxy
- oxazolo
- pyrimidin
- chloro
- dimethyl
- Prior art date
Links
- 208000009304 Acute Kidney Injury Diseases 0.000 title abstract 2
- 208000033626 Renal failure acute Diseases 0.000 title abstract 2
- 201000011040 acute kidney failure Diseases 0.000 title abstract 2
- 208000012998 acute renal failure Diseases 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- -1 3-Chloro-phenoxy Chemical group 0.000 title 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 title 1
- WRBZNIUFAKIIQG-UHFFFAOYSA-N 2-[4-[5-(3-chlorophenoxy)-[1,3]oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethylphenoxy]acetic acid Chemical compound CC1=C(OCC(O)=O)C(C)=CC(C=2OC3=NC(OC=4C=C(Cl)C=CC=4)=NC=C3N=2)=C1 WRBZNIUFAKIIQG-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La présente invention concerne de l'acide {4- [5- (3-chloro-phénoxy) -oxazolo [5,4-d] pyrimidin -2-yl] -2,6-diméthyl-phénoxy}-acétique ou un sel pharmaceutiquement acceptable de celui-ci destiné à être utilisé dans la prévention ou le traitement d'une insuffisance rénale aiguë) (ira). L'invention porte également sur un médicament et une composition pharmaceutique de celui-ci.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20130306417 EP2862574A1 (fr) | 2013-10-15 | 2013-10-15 | Acide {4-[5-(3-chloro-phénoxy)-oxazolo[5,4 d]pyrimidin-2-yl]-2,6-diméthyl-phénoxy}-acétique pour son utilisation dans la prévention ou le traitement de l'insuffisance rénale aiguë |
| PCT/EP2014/072078 WO2015055694A1 (fr) | 2013-10-15 | 2014-10-15 | Acide 4- [5- (3-chloro-phénoxy) -oxazolo [5,4-d] pyrimidin -2-yl] -2,6-diméthyl-phénoxy}-acétique destiné à être utilisé dans la prévention ou le traitement d'une insuffisance rénale aiguë |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA39032A1 true MA39032A1 (fr) | 2017-04-28 |
| MA39032B2 MA39032B2 (fr) | 2020-10-28 |
Family
ID=49488539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39032A MA39032B2 (fr) | 2013-10-15 | 2014-10-15 | Acide 4- [5- (3-chloro-phénoxy) -oxazolo [5,4-d] pyrimidin -2-yl] -2,6-diméthyl-phénoxy}-acétique destiné à être utilisé dans la prévention ou le traitement d'une insuffisance rénale aiguë |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9782411B2 (fr) |
| EP (2) | EP2862574A1 (fr) |
| JP (1) | JP6458016B2 (fr) |
| KR (1) | KR102348608B1 (fr) |
| CN (1) | CN105658220B (fr) |
| AR (1) | AR098028A1 (fr) |
| AU (1) | AU2014336254B9 (fr) |
| BR (1) | BR112016007669B1 (fr) |
| CA (1) | CA2926211C (fr) |
| CL (1) | CL2016000724A1 (fr) |
| CR (1) | CR20160172A (fr) |
| DK (1) | DK3057591T3 (fr) |
| EA (1) | EA032012B1 (fr) |
| ES (1) | ES2898403T3 (fr) |
| FI (1) | FI3057591T3 (fr) |
| IL (2) | IL244686B (fr) |
| MA (1) | MA39032B2 (fr) |
| MX (1) | MX383252B (fr) |
| PH (1) | PH12016500563A1 (fr) |
| PT (1) | PT3057591T (fr) |
| SG (1) | SG11201602263TA (fr) |
| TN (1) | TN2016000110A1 (fr) |
| TW (1) | TWI685340B (fr) |
| WO (1) | WO2015055694A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109789117B (zh) * | 2016-10-05 | 2022-08-23 | 米托布里奇公司 | 治疗急性肾损伤的方法 |
| CN106905348B (zh) * | 2017-02-13 | 2018-12-04 | 牡丹江医学院 | 一种预防和治疗急性肾损伤的药物及其制备方法和用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10033353A1 (de) | 2000-07-08 | 2002-01-24 | Aventis Pharma Gmbh | Breit einsetzbares Verfahren zur Identifizierung von Modulatoren von G-Protein gekoppelten Rezeptoren |
| MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
| EP2295418A1 (fr) | 2003-11-21 | 2011-03-16 | Actelion Pharmaceuticals Ltd. | Dérivés de 5-(benz-(z)-ylidène)-thiazolidin-4-one comme agents immunosuppresseurs |
| SG182484A1 (en) * | 2010-01-14 | 2012-08-30 | Sanofi Sa | Carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring |
-
2013
- 2013-10-15 EP EP20130306417 patent/EP2862574A1/fr not_active Withdrawn
-
2014
- 2014-10-15 FI FIEP14784452.6T patent/FI3057591T3/fi active
- 2014-10-15 TN TN2016000110A patent/TN2016000110A1/en unknown
- 2014-10-15 CA CA2926211A patent/CA2926211C/fr active Active
- 2014-10-15 US US15/027,964 patent/US9782411B2/en active Active
- 2014-10-15 MX MX2016004778A patent/MX383252B/es unknown
- 2014-10-15 MA MA39032A patent/MA39032B2/fr unknown
- 2014-10-15 WO PCT/EP2014/072078 patent/WO2015055694A1/fr not_active Ceased
- 2014-10-15 AR ARP140103825A patent/AR098028A1/es unknown
- 2014-10-15 TW TW103135715A patent/TWI685340B/zh active
- 2014-10-15 EP EP14784452.6A patent/EP3057591B1/fr active Active
- 2014-10-15 AU AU2014336254A patent/AU2014336254B9/en active Active
- 2014-10-15 BR BR112016007669-9A patent/BR112016007669B1/pt active IP Right Grant
- 2014-10-15 KR KR1020167011272A patent/KR102348608B1/ko active Active
- 2014-10-15 CN CN201480056551.8A patent/CN105658220B/zh active Active
- 2014-10-15 ES ES14784452T patent/ES2898403T3/es active Active
- 2014-10-15 EA EA201690762A patent/EA032012B1/ru not_active IP Right Cessation
- 2014-10-15 DK DK14784452.6T patent/DK3057591T3/da active
- 2014-10-15 JP JP2016521603A patent/JP6458016B2/ja active Active
- 2014-10-15 SG SG11201602263TA patent/SG11201602263TA/en unknown
- 2014-10-15 PT PT147844526T patent/PT3057591T/pt unknown
-
2016
- 2016-03-21 IL IL244686A patent/IL244686B/en active IP Right Grant
- 2016-03-28 PH PH12016500563A patent/PH12016500563A1/en unknown
- 2016-03-29 CL CL2016000724A patent/CL2016000724A1/es unknown
- 2016-04-14 CR CR20160172A patent/CR20160172A/es unknown
-
2021
- 2021-04-06 IL IL282097A patent/IL282097A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201691242A1 (ru) | Фармацевтические композиции, содержащие azd9291 | |
| BR112015016315A2 (pt) | fluoro-[1,3]oxazinas como inibidores de bace1 | |
| BR112015011036A2 (pt) | derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais | |
| BR112015020118A2 (pt) | derivados de 2-aminopirimidina para o tratamento de infecções virais | |
| CL2015000578A1 (es) | Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer. | |
| EA201501032A1 (ru) | Фармацевтическая композиция, способы лечения и ее применения | |
| BR112013032122A2 (pt) | liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos | |
| MA43828B1 (fr) | Agents thérapeutiques pour maladies neurodégénératives | |
| MA42287B1 (fr) | Traitement de patients atteints de diabète sucré de type 2 | |
| MX388825B (es) | Uso y dosificacion de agentes terapeuticos para endometriosis. | |
| BR112019025578A2 (pt) | Mesembrenol e/ou mesembranol para profilaxia e tratamento de pacientes que sofrem de epilepsia e doenças associadas | |
| MA43876B1 (fr) | Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale | |
| MA39032A1 (fr) | Acide 4- [5- (3-chloro-phénoxy) -oxazolo [5,4-d] pyrimidin -2-yl] -2,6-diméthyl-phénoxy}-acétique destiné à être utilisé dans la prévention ou le traitement d'une insuffisance rénale aiguë | |
| MA39447B1 (fr) | Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
| MA35636B1 (fr) | Formulation à libération immédiate de 4-méthyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-méthyl- 1h-imidazol-1-yl)-3-(trifluorométhyl)phényl]benzamide | |
| MX393629B (es) | Beta-horquilla peptidomimetica con actividad inhibidora de elastasa y formas de dosificacion en aerosol de la misma. | |
| MA45639B1 (fr) | Combinaison d'antagonistes purs du récepteur 5-ht6 avec des inhibiteurs d'acétylcholinestérase | |
| MA39448A1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
| MA35850B1 (fr) | Nouvelle utilisation thérapeutique d'antagonistes du récepteur p75 | |
| MA39833A (fr) | Nouvelle utilisation du n,n-bis-2-mercaptoéthyl isophtalamide | |
| SG195288A1 (en) | [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid | |
| MA44850A (fr) | Composition ophtalmique comprenant une combinaison synergique de glycogène et d'acide hyaluronique ou d'un sel de celui-ci | |
| BR112016007588A2 (pt) | formas de dosagem farmacêutica compreendendo sódio 1-[6- (morfolina-4-il) pirimidina-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato | |
| EA202091903A1 (ru) | Кристаллическая форма битегравир-натрия | |
| EA202092756A1 (ru) | Конденсированные бициклические соединения для применения в качестве ингибиторов убиквитин-специфической пептидазы 30 |